EA200500533A1 - Пептидные производные - ингибиторы слияния при вич-инфекции - Google Patents
Пептидные производные - ингибиторы слияния при вич-инфекцииInfo
- Publication number
- EA200500533A1 EA200500533A1 EA200500533A EA200500533A EA200500533A1 EA 200500533 A1 EA200500533 A1 EA 200500533A1 EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A1 EA200500533 A1 EA 200500533A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitors
- mercury
- hiv infection
- peptide derivatives
- derivatives
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 229910052753 mercury Inorganic materials 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Данное изобретение относится к производным gp41-пептидов, которые представляют собой ингибиторы вирусной инфекции и/или обладают антифузогенными свойствами. В частности, данное изобретение относится к производным gp41-пептидов, обладающим ингибирующим действием по отношению к вирусу иммунодефицита человека (ВИЧ) и вирусу иммунодефицита обезьян (ВИО) и имеющим увеличенную продолжительность действия при лечении соответствующих вирусных инфекций.Отчет о международном поиске был опубликован 2004.08.12.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41279702P | 2002-09-24 | 2002-09-24 | |
PCT/US2003/029815 WO2004029201A2 (en) | 2002-09-24 | 2003-09-23 | Peptide derivative fusion inhibitors of hiv infection |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200500533A1 true EA200500533A1 (ru) | 2005-12-29 |
EA007918B1 EA007918B1 (ru) | 2007-02-27 |
Family
ID=32043189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200500533A EA007918B1 (ru) | 2002-09-24 | 2003-09-23 | Пептидные производные-ингибиторы слияния при вич-инфекции |
Country Status (15)
Country | Link |
---|---|
US (3) | US7575750B2 (ru) |
EP (1) | EP1542718B1 (ru) |
JP (2) | JP5385497B2 (ru) |
CN (1) | CN1327897C (ru) |
AP (1) | AP2203A (ru) |
AU (2) | AU2003275116A1 (ru) |
BR (1) | BR0314657A (ru) |
CA (1) | CA2500248C (ru) |
CR (1) | CR7806A (ru) |
EA (1) | EA007918B1 (ru) |
ES (1) | ES2558680T3 (ru) |
IL (1) | IL167527A (ru) |
NZ (1) | NZ539539A (ru) |
WO (1) | WO2004029201A2 (ru) |
ZA (1) | ZA200503118B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741453B2 (en) | 2001-05-31 | 2010-06-22 | Conjuchem Biotechnologies, Inc. | Long lasting fusion peptide inhibitors for HIV infection |
NZ539539A (en) * | 2002-09-24 | 2006-11-30 | Frontier Biotechnologies Co | HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties |
CN100455594C (zh) * | 2005-12-14 | 2009-01-28 | 中国人民解放军军事医学科学院生物工程研究所 | 抑制hiv病毒融合的多肽及其用途 |
CN1793170A (zh) * | 2005-12-14 | 2006-06-28 | 中国人民解放军军事医学科学院生物工程研究所 | 抑制hiv病毒融合的多肽及其用途 |
US20070269863A1 (en) * | 2005-12-22 | 2007-11-22 | Bridon Dominique P | Process for the production of preformed conjugates of albumin and a therapeutic agent |
WO2008144590A2 (en) * | 2007-05-16 | 2008-11-27 | Conjuchem Biotechnologies Inc. | Long lasting modified antifusogenic peptide for preventing hiv infection |
WO2012022040A1 (zh) * | 2010-08-19 | 2012-02-23 | 清华大学 | Hiv-1病毒膜融合抑制剂及其应用 |
CN103664701A (zh) * | 2013-11-29 | 2014-03-26 | 成都普康生物科技有限公司 | [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线 |
CN114306225A (zh) * | 2019-05-07 | 2022-04-12 | 前沿生物药业(南京)股份有限公司 | 稳定的艾博韦泰组合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
US3791667A (en) * | 1972-05-04 | 1974-02-12 | H Haviland | Retractable vehicle passenger cushioning system |
US5612034A (en) | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
JPH06509551A (ja) | 1991-04-05 | 1994-10-27 | ジェネンテク,インコーポレイテッド | Gp II↓bIII↓aに対する高い特異性を有する血小板凝集阻害剤 |
US5624902A (en) | 1995-06-07 | 1997-04-29 | Torrey Pines Institute For Molecular Studies | Peptide inhibitors of calmodulin |
AU723537B2 (en) * | 1995-06-07 | 2000-08-31 | Trimeris Inc. | The treatment of HIV and other viral infections using combinatorial therapy |
US6268479B1 (en) | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
US6281331B1 (en) | 1998-03-23 | 2001-08-28 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
AU764103B2 (en) * | 1999-05-17 | 2003-08-07 | Conjuchem Biotechnologies Inc. | Long lasting anti-angiogenic peptides |
EP1591453A1 (en) * | 1999-05-17 | 2005-11-02 | ConjuChem Inc. | Modified peptides yy and conjugates thereof |
AU761591B2 (en) * | 1999-05-17 | 2003-06-05 | Conjuchem Biotechnologies Inc. | Long lasting fusion peptide inhibitors of viral infection |
EA003922B1 (ru) * | 1999-05-17 | 2003-10-30 | Конджачем, Инк. | Продолжительно действующие инсулинотропные пептиды |
US6750008B1 (en) * | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
CN1172717C (zh) * | 2000-08-18 | 2004-10-27 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
NZ539539A (en) * | 2002-09-24 | 2006-11-30 | Frontier Biotechnologies Co | HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties |
-
2003
- 2003-09-23 NZ NZ539539A patent/NZ539539A/en not_active IP Right Cessation
- 2003-09-23 CA CA2500248A patent/CA2500248C/en not_active Expired - Lifetime
- 2003-09-23 AU AU2003275116A patent/AU2003275116A1/en not_active Abandoned
- 2003-09-23 US US10/667,966 patent/US7575750B2/en active Active
- 2003-09-23 BR BR0314657-0A patent/BR0314657A/pt not_active IP Right Cessation
- 2003-09-23 JP JP2004540158A patent/JP5385497B2/ja not_active Expired - Lifetime
- 2003-09-23 CN CNB038164345A patent/CN1327897C/zh not_active Expired - Lifetime
- 2003-09-23 EP EP03759385.2A patent/EP1542718B1/en not_active Expired - Lifetime
- 2003-09-23 AP AP2005003291A patent/AP2203A/xx active
- 2003-09-23 EA EA200500533A patent/EA007918B1/ru not_active IP Right Cessation
- 2003-09-23 WO PCT/US2003/029815 patent/WO2004029201A2/en active Application Filing
- 2003-09-23 ES ES03759385.2T patent/ES2558680T3/es not_active Expired - Lifetime
-
2005
- 2005-03-17 IL IL167527A patent/IL167527A/en active IP Right Grant
- 2005-04-18 ZA ZA200503118A patent/ZA200503118B/en unknown
- 2005-04-22 CR CR7806A patent/CR7806A/es unknown
-
2009
- 2009-09-25 US US12/567,250 patent/US8470527B2/en active Active
-
2010
- 2010-03-04 AU AU2010200823A patent/AU2010200823B2/en not_active Ceased
- 2010-04-30 JP JP2010105068A patent/JP2010209097A/ja active Pending
-
2013
- 2013-06-25 US US13/926,698 patent/US20140187476A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006505536A (ja) | 2006-02-16 |
ZA200503118B (en) | 2006-11-29 |
BR0314657A (pt) | 2005-08-02 |
US7575750B2 (en) | 2009-08-18 |
JP2010209097A (ja) | 2010-09-24 |
EP1542718A2 (en) | 2005-06-22 |
NZ539539A (en) | 2006-11-30 |
AU2003275116A1 (en) | 2004-04-19 |
US20140187476A1 (en) | 2014-07-03 |
IL167527A (en) | 2013-12-31 |
US8470527B2 (en) | 2013-06-25 |
AU2010200823B2 (en) | 2011-12-15 |
ES2558680T3 (es) | 2016-02-08 |
AP2005003291A0 (en) | 2005-06-30 |
AU2010200823A1 (en) | 2010-03-25 |
WO2004029201A2 (en) | 2004-04-08 |
CA2500248A1 (en) | 2004-04-08 |
US20050089840A1 (en) | 2005-04-28 |
CN1327897C (zh) | 2007-07-25 |
CN1668330A (zh) | 2005-09-14 |
CR7806A (es) | 2007-09-07 |
EP1542718A4 (en) | 2011-04-06 |
AP2203A (en) | 2011-01-31 |
US20110003735A1 (en) | 2011-01-06 |
EA007918B1 (ru) | 2007-02-27 |
EP1542718B1 (en) | 2015-11-11 |
CA2500248C (en) | 2013-03-19 |
JP5385497B2 (ja) | 2014-01-08 |
WO2004029201A3 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112267T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c | |
DE60216151D1 (de) | Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion | |
IS7532A (is) | Heterósýklískir súlfónamíð lifrarbólgu C-veirutálmar | |
EA200700243A1 (ru) | Способы лечения гепатита с | |
CY1112632T1 (el) | Αναστολεις ασπαρτυλ πρωτεασης | |
DE60336550D1 (de) | Inhibitoren des hepatitis-c-virus | |
CY1108036T1 (el) | Κυτταρικη συσσωρευση φωσφονικων αναλογων ενωσεων αναστολεα πρωτεασης του ιου ανοσολογικης ανεπαρκειας του ανθρωπου (hiv) και οι ενωσεις ως τετοιες | |
CY1111212T1 (el) | Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ | |
MA31666B1 (fr) | Cyclic peptide cxcr4 antagonists | |
ATE327246T1 (de) | Hepatitis c tripeptid inhibitoren | |
ATE476983T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege | |
ATE413411T1 (de) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
HUP0202502A2 (hu) | Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására | |
ECSP093601A (es) | Proteínas derivadas del virus del síndrome de mancha blanca y sus usos | |
EA199700222A1 (ru) | Сульфонилалканоиламиногидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы | |
CR7806A (es) | Inhibidores de la fusion de derivados peptidos de la infeccion vih | |
BR9607625A (pt) | Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila | |
DE60130641D1 (de) | Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung | |
WO2007002172A3 (en) | Hiv-1 protease inhibitors | |
MX9700414A (es) | Agentes antivirales de difluoroestatona. | |
WO2003052122A3 (en) | Gp41 inhibitor | |
EA202191711A1 (ru) | Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток | |
EA200401611A1 (ru) | Пептиды gp41 и способы ингибирования слияния вич с клетками-мишенями на их основе | |
WO2005060541A3 (en) | Peptides and methods for inducing cellular resistance to infection | |
WO2002034909A3 (en) | Engineered chimera of hiv protein fragments and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |